🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Anushka Naidoo

Centre for the AIDS Programme of Research in South Africa

ORCID: 0000-0001-9550-9501

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial”.

INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial

BMJ Open(2022)10.1136/bmjopen-2022-067765

N/A

0.484DataRank · unranked

7 citations

Kelly E. Dooley, Kogieleum Naidoo, Nesri Padayatchi, Nonhlanhla Yende‐Zuma, Rubeshan Perumal +4 more

Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study

The Lancet HIV(2025)10.1016/s2352-3018(24)00312-6

N/A

0.315DataRank · unranked

5 citations

Hylke Waalewijn, Kogieleum Naidoo, Marothi Letsoalo, Gabriela Cromhout, Leora Sewnarain +8 more

Dolutegravir once daily with rifampicin for HIV and tuberculosis

The Lancet HIV(2023)10.1016/s2352-3018(23)00115-7

N/A

0.241DataRank · unranked

4 citations

Kelly E Dooley, Anushka Naidoo

Fixed-dose combination bictegravir–emtricitabine–tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial

The Lancet HIV(2025)10.1016/s2352-3018(25)00200-0

N/A

0.165DataRank · unranked

2 citations

Kogieleum Naidoo, Marothi Letsoalo, Roeland E. Wasmann, Gillian Dorse, Rubeshan Perumal +33 more

Pregnancy rates and outcomes in a longitudinal HIV cohort in the context of evolving antiretroviral treatment provision in South Africa

BMC Pregnancy and Childbirth(2022)10.1186/s12884-022-04829-2

N/A

0DataRank · unranked

6 citations

Nonhlanhla Yende‐Zuma, Ayesha B. M. Kharsany, Hlengiwe Shozi, Duduzile Nkosi, Anushka Naidoo +3 more

Strategies implemented for accurate dispensing of an investigational new drug in a multi-site HIV prevention clinical trial

Contemporary Clinical Trials Communications(2021)10.1016/j.conctc.2021.100859

N/A

0DataRank · unranked

1 citations

Jayajothi Moodley, Aruna Bhoola, Rebecca Sakwa, Jeeva Moodley, Jasmin Lynn Sukdao +8 more

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin

Clinical Infectious Diseases(2025)10.1093/cid/ciaf732

N/A

0DataRank · unranked

0 citations

Ivan Nicholas Nkuhairwe, Marothi Peter Letsoalo, Kogieleum Naidoo, R Perumal, James F Rooney +32 more